127-79-7
Chemical Structure
Sulfamerazine
Synonym(s): RP2632
- CAS No.: 127-79-7
- Formula:C11H12N4O2S
- Molecular Weight:264.30
IUPAC Name: 4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide
InChIKey: QPPBRPIAZZHUNT-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(N)C=C1)(NC2=NC=CC(C)=N2)=O
Biological Activity: Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sulfamerazine | 99.82% | Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamerazine (Standard) | 99.72% | Sulfamerazine (Standard) is the analytical standard of Sulfamerazine. This product is intended for research and analytical applications. Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamerazine-13C6 | 99.11% | Sulfamerazine-13C6 (RP2632-13C6) is 13C labeled Sulfamerazine (HY-B0512). Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamerazine-d4 | 99.00% | Sulfamerazine-d4 is a deuterium labeled Sulfamerazine. Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Singh P, et al. Sulfamerazine as a Potential Modulator against α-Synuclein Aggregation and Associated Toxicity. ACS Chem Neurosci. 2025;16(5):880-894. [Content Brief]
- [2]. Hageman PO, et al. Sulfamerazine: A Clinical Study of Its Pharmacodynamics, Therapeutic Value and Toxicity. JAMA. 1943 Oct 9;123(6):325-330.
